University of Melbourne receives $4.4 million funding boost from AEA program
Posted: 8 July 2025 University of Melbourne researchers have secured $4.4M from Australia’s Economic Accelerator (AEA) Innovate program. The funding will enable collaboration with industry partners to bring three research-based technologies to market. The funding had been allocated…
Monash University to lead $25 million mobile CT scanner development project
Posted: 8 July 2025 Monash University has stated it will “lead the design of a first-of-its-kind mobile CT scanner” with Micro-X as part of a $25 million development project. The initiative is being supported by the US Advanced…
Peter Mac researchers progress CAR T-Cell therapy for solid tumours
Posted: 7 July 2025 Researchers at Peter MacCallum Cancer Centre have advanced efforts to harness CAR T-cell therapy against solid tumour cancers, overcoming a major barrier that had limited the treatment’s use beyond blood cancers. The team, led…
Amplia Therapeutics announces additional partial response in Pancreatic Cancer trial
Posted: 7 July 2025 Amplia Therapeutics announced that dosing had been completed for the first group of patients in its ACCENT Phase 2 clinical study evaluating AMP945 combined with gemcitabine and nab-paclitaxel in advanced pancreatic cancer. The ACCENT…
Ego Pharmaceuticals expands local manufacturing with $156 Million investment
Posted: 2 July 2025 Australian skincare manufacturer Ego Pharmaceuticals has unveiled a decade-long $156 million investment to expand its domestic production capabilities, opening the advanced Zorzi Innovation Centre (ZInC) alongside new sustainability and manufacturing upgrades. The announcement was…
IDT opens Australia’s first anti-body drug conjugate factory
Posted: 2 July 2025 Victoria’s Government announced that IDT Australia has inaugurated the nation’s first facility dedicated to the manufacture of antibody-drug conjugates (ADCs) for oncology therapies. The IDT Ehrlich Bioconjugation Centre, located in Victoria, had been officially…
Atmo Biosciences gas capsule receives FDA clearance
Posted: 30 June 2025 Atmo Biosciences has been granted clearance by the United States Food and Drug Administration (FDA) under the 510(k) process for its Atmo Gas Capsule System, enabling its first product to be marketed and sold…
Noxopharm advances HERACLES clinical trial recruitment
Posted: 30 June 2025 Noxopharm Limited (ASX:NOX), a clinical-stage biotechnology firm, has announced rapid progress in the recruitment phase of its HERACLES clinical trial, staying on track with its timeline. HERACLES is a groundbreaking first-in-human study for SOF-SKN™,…
BioForum spotlight: From wonder to impact – quantum and AI in medicines discovery and beyond
Posted: 25 June 2025 This article recaps BioMelbourne Network’s BioForum “Stepping off the ledge – Quantum, AI technologies and the future of drug discovery.” It highlights key takeaways from the panel, insights from experts across quantum science, AI,…
CSL’s Andembry™ wins FDA Approval as first-of-its-kind monthly preventative for Hereditary Angioedema
Posted: 23 June 2025 CSL announced that its novel monoclonal antibody therapy, Andembry™ (garadacimab-gxii), had been granted approval by the U.S. Food and Drug Administration (FDA) for the prevention of HAE attacks in patients aged 12 and older.…
Inoviq’s new Cancer treatments kills 88% of Breast and Lung Cancer Cells in lab tests
Posted: 23 June 2025 INOVIQ Limited announced that a significant milestone had been reached in its exosome-based therapeutic programme, with laboratory studies confirming the treatment’s potent activity against two aggressive cancer types. The preclinical candidate, utilising CAR-NK-derived extracellular…
Wavewise Analytics awarded $996,995 in funding through TTRA initiative
Posted: 23 June 2025 Wavewise Analytics has been awarded $996,995 in funding through MTPConnect’s Targeted Translation Research Accelerator (TTRA) — an important initiative funded by the Australian Government’s Medical Research Future Fund (MRFF). This funding will accelerate the…
